After the development of a highly sensitive RT-PCR test for the new coronavirus SARS-Cov-2 and a lysis buffer that replaces conventional RNA extraction, Cube Dx is now preparing for the upcoming challenges of the next cold season: a broad screening for respiratory viruses and bacteria will enable physicians to rapidly stratify patients with respiratory symptoms.
Cube Dx will use its proven concept of compact sequencing to provide such syndromic testing of more than 20 different viruses and bacteria. The staged concept of a highly multiplexed RT-PCR to single out positive samples and a follow-up in-depth analysis of the amplified RNA will combine a high-througput screening with highly multiplexed results.
The detailed information of the test will simplify the testing of patients and shorten the time to individual therapy. The potential impact of Cube Dx' development convinced the Austrian Agency for Research Funding (FFG) and Cube Dx won a grant for the development of the test within Austria's Covid19 emergency call (https://www.ffg.at/content/COVID19-foerderentscheidung).